SCHEMBL6632235

SCHEMBL6632235

C[C@@](O)(CCc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
AR P10275 1/20 0.50
SLC13A5 Q86YT5 3/20 0.49
KEAP1 Q14145 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
GRM2 Q14416 1/20 0.46
GRM3 Q14832 1/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6628038 1.00 ALDH1A1 (0.50) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL5475208 1.00 ALDH1A1 (0.50) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL28351862 0.88 POLB (0.53) ALDH1A1KEAP1NPC1RAB9APOLB
SCHEMBL22781383 0.88 ALDH1A1 (0.52) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL27957913 0.86 AR (0.47) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL5619673 0.86 MAPT (0.52) POLBMAPTGRM2GRM3MEN1
SCHEMBL6912517 0.86 AR (0.47) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL6914641 0.86 AR (0.47) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL20176094 0.85 NPC1 (0.46) ALDH1A1ARSLC13A5KEAP1NPC1
SCHEMBL9781113 0.85 MAPT (0.55) POLBMAPTGRM2GRM3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE ALDH1A1 4046/4885AR 4095/4885SLC13A5 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.